|Bid||0.00 x 1300|
|Ask||0.00 x 2900|
|Day's Range||49.13 - 49.73|
|52 Week Range||41.45 - 61.71|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||9.47|
|Earnings Date||Feb 06, 2023 - Feb 10, 2023|
|Forward Dividend & Yield||1.60 (3.23%)|
|Ex-Dividend Date||Nov 03, 2022|
|1y Target Est||54.78|
Pfizer (NYSE: PFE) is a 173-year-old company with a huge portfolio of products. This year, Pfizer has dropped about 16%, in line with the S&P 500. In fact, there are three reasons Pfizer stock could crush the broader market in 2023.
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.